Videos
Iceland’s iStopMM Study Revises Definition of Free Light Chains in Serum and Light Chain Monoclonal Gammopathy of Undetermined Significance (MGUS)
Dr. Thorir Einarsson Long discusses an aspect of the iStopMM study, a large population-based trial, that focused on light chain monoclonal…
Videos
Latest Insights from CARTITUDE-2 Trial on Ciltacabtagene Autoleucel in Multiple Myeloma — Cohort A and Early Relapse (Cohort B) Updates
Dr. Jens Hillengass presents results of the phase II CARTITUDE-2 Trial, including updated efficacy and safety data from the trial’s cohorts A and B, both…
Videos
Myeloma Treatment: The STEM Trial Phase II Study on Cevostamab Consolidation After BCMA CAR T-Cell Therapy
Dr. Adam D. Cohen discusses a novel approach using Cevostamab, a bispecific antibody that targets the antigen FcRH5. The aim of the study is to use Cevostamab along with CAR T-cell…
Videos
Updates in Myeloma Treatment: BMS-986393 CAR T-Cell Therapy Shows Promise in Phase I Study for Relapsed/Refractory Patients
Dr. Susan Bal discusses update safety and efficacy data from a phase I, first-in-human, multicenter, open-label, dose-finding study evaluating BMS-986393…
News Article
At the end of every month, the International Myeloma Foundation Newsroom will feature a wrap-up of some of the most fascinating studies about multiple myeloma from medical journals. Here is the December 2023 edition.
The IMF team of medical editors has provided overviews of key studies. Yet, we…
IMF Person
Poornima is passionate about the application of science, technology, and data towards building a healthier planet. She is a tenacious entrepreneur, skilled at leading dynamic teams through transformative changes and transitions.
As CEO, Board Director, and Co-founder of Trace Genomics, she…
Videos
Impact of Dexamethasone (Dex) Dose Strength on Outcomes in Newly Diagnosed Multiple Myeloma (NDMM): A Secondary Analysis of SWOG Studies S0777 and S1211
Rahul Banerjee, MD discusses the impact of different strengths of dexamethasone (dex) on newly diagnosed multiple myeloma (NDMM).…
Videos
Optimizing Myeloma Treatment: Pomalidomide-based Regimens Compared in Asian Myeloma Network (AMN) Study — a Phase III Analysis of PCd vs. Pd for Relapse or Refractory Myeloma (RRMM)
Dr. Wee-Joo Chng discusses a randomized phase III trial that compares the use of pomalidomide,…
News Article
STUDIO CITY, December 20, 2023—The International Myeloma Foundation (IMF) proudly announces the publication of a new study addressing disparities among African American patients with multiple myeloma in Blood Cancer Journal.
The study is authored by IMF Chief…
News Article
2023 Miracles for Myeloma 5K Run/Walk
For 11 years, Sheree & Ron Pask have been raising funds to benefit the global myeloma community
By Sylvia Dsouza, IMF Vice President, Development
In October 2023, the Miracles for Myeloma 5K Run/Walk…
News Article
Sarclisa Achieves Milestone in Phase III IMROZ Trial for Myeloma Treatment
Sarclisa® (isatuximab-irfc), when added to the combination of Velcade (bortezomib), Revlimid (lenalidomide), and dexamethasone (VRd), has been found to significantly reduce…
News Article
ELREXFIO™ (elranatamab-bcmm) has been granted conditional marketing authorization by the European Commission for the treatment of relapsed or refractory multiple myeloma (RRMM) in adults. This approval follows positive findings from the MagnetisMM-3 study, a phase II trial.
ELREXFIO is an…
Page
For more than a decade, the International Myeloma Foundation has attended the American Society of Hematology (ASH) annual meeting, an exciting convergence of thousands of healthcare professionals from around the world. Explore this page to learn about the latest blood cancer…
News Article
Poster Abstracts 1977 and 2418 to be presented on December 9 at the San Diego Convention Center
STUDIO CITY, CA, December 7, 2023 — The International Myeloma Foundation (IMF) is proud to announce that Semaje Testamark (Emory University School of Medicine—Atlanta, GA), one…
Videos
Early Screening for Myeloma: Advantages, Impact, and Benefits
Myeloma expert Dr. Brian G.M. Durie explores the advantages of early screening for myeloma and its potential benefits for patients and their families.
Dr. Durie discusses the groundbreaking International…
News Article
NLB Members Convene for the 19th Meeting of Impact and Innovation
Myeloma nurse experts collaborate to support nurses and empower patients at “NLB XIX”
By Diane Moran, IMF Senior Vice President, Business Relationship Management
Members of the…
Videos
What is the Black Swan Research Initiative's immune system study to understand early myeloma development?
Myeloma expert Dr. Brian G.M. Durie delves into groundbreaking research from the International Myeloma Foundation (IMF).
Explore an exciting initiative focused on…
News Article
The Inflation Reduction Act
An early guide for patients with myeloma
By Danielle Doheny, IMF Director, Public Policy & Advocacy
You may have heard rumblings about upcoming changes to the Medicare program. The recently enacted Inflation…
News Article
Mayo Clinic’s PragMMatic Study Accruing Newly Diagnosed Multiple Myeloma Patients
A new clinical trial administered by the Mayo Clinic, the PragMMatic Study, is now accruing newly diagnosed multiple myeloma (NDMM) patients. Led by the IMF’s International Myeloma Working Group (IMWG) members…
News Article
Blenrep Shows Promise in DREAMM-7 Trial for Relapsed Myeloma Patients
On November 27, 2023, GSK announced positive results from the DREAMM-7 phase III trial evaluating belantamab mafodotin as a second-line treatment for relapsed or refractory multiple myeloma. The trial demonstrated a…
News Article
M-Power Makes Impact
The IMF’s health equity initiative holds NYC events and celebrates Medical Student Scholars
By Dr. Joseph Mikhael, IMF Chief Medical Officer
The IMF launched its M-Power Initiative to help address health disparities in…
News Article
At the end of every month, the International Myeloma Foundation Newsroom will feature a wrap-up of some of the most fascinating studies about multiple myeloma from medical journals. Here is our first edition.
The IMF team of medical editors have summarized key findings and conclusions of…
Page
What Is Bendamustine and To Whom Is It Given?
TREANDA® or BENDEKA® (bendamustine) is a type of FDA-approved chemotherapy to treat chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) in the U.S. It has been approved in Europe as a first-line treatment for multiple…
Videos
Evaluating Risk and Progression in High-Risk Smoldering Myeloma
Myeloma expert Dr. Brian G.M. Durie addresses key questions and concerns surrounding this critical stage of myeloma; high-risk smoldering.
Learn about the 20/2/20 criteria, which helps predict the risk of…
News Article
#kNOwMyeloma Reaches Nearly 20 MILLION People in 64 Countries!
The IMF’s 2023 Blood Cancer Awareness Month
By Peter Anton, IMF Vice President, Marketing
For the 2023 Blood Cancer Awareness Month (BCAM), the International Myeloma Foundation (IMF…
News Article
IMF Supports the Bipartisan Cancer Drug Parity Act for Improved Access to Cancer Treatments
The International Myeloma Foundation (IMF) strongly endorses the Cancer Drug Parity Act, co-led by Representatives Glenn Grothman, Suzanne Bonamici, Gus Bilirakis, Joe Morelle, Brian Fitzpatrick, Brian…
News Article
Washington, D.C. November 8, 2023 – In a significant stride toward ensuring equitable access to cancer treatments, Members of the House of Representatives reintroduced the Cancer Drug Parity Act today. The bill has garnered widespread endorsement from prominent healthcare…
News Article
The Role of the Care Partner in Myeloma
Care partners walk alongside their loved ones to help them live well with myeloma
By Robin Tuohy, IMF Vice President, Support Groups
Who is a care partner?
Care partners, also known as “caregivers,” are individuals who provide…
Videos
M-Power Detroit Community Event On Health Empowerment
Focusing on awareness of multiple myeloma in the African American community and living a healthier life.
The M-Power Project realizes the IMF Diversity Initiative's vision, enhancing outcomes for African-American myeloma patients…
News Article
STUDIO CITY, CA, November 3, 2023 – The International Myeloma Foundation (IMF) is pleased to announce that the organization has been selected as the winner of the 2023 Sanofi HealthEquity Accelerator Award for its Shared Decision-Making among African American…
Page
What Is Elrexfio? ELREXFIO® (also known as elranatamab-bcmm, the generic drug name) is a B-cell maturation antigen (BCMA)-CD3-directed bispecific antibody immunotherapy. In August 2023, the U.S. FDA granted accelerated approval of Elrexfio for the treatment of adult patients with…
Videos
Disparities Made Simple
Myeloma Made Simple: What Health Disparities Do Minority Patients Face?
Disparities in Myeloma Made Simple! Join Dr. Joseph Mikhael in the latest episode of "Myeloma Made Simple" as he explores the inequities in healthcare faced by socially disadvantaged…
Videos
The International Myeloma Foundation's Asian Myeloma Network
Enhancing multiple myeloma care in Asia and globally.
In this week's #AskDrDurie Myeloma Expert Dr. Brian G.M. Durie breaks down the IMF Asian Myeloma Network (AMN) Summit, where experts discuss groundbreaking…
Page
What Is Talvey? TALVEY® (also known as talquetamab-tvgs, the generic drug name, or "tal" for short) is a bispecific monoclonal antibody with a novel target, GPRC5D, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of…
Videos
The Power of Emotional Freedom Technique
Clinical Psychologist Rebecca Rooney, explores the power of Emotional Freedom Technique (EFT), also known as tapping.
Whether you're a myeloma patient, care partner or just seeking emotional healing, this video provides practical insights into using…
Videos
Replay a fascinating discussion with Dr. Joseph Mikhael, the Chief Medical Officer of the International Myeloma Foundation, as he delves into the latest advancements in multiple myeloma research. Discover how cutting-edge techniques like mass spectrometry are revolutionizing diagnosis and treatment…
Videos
Join us for a replay of a Facebook Live event featuring Beth Faiman, a nurse practitioner from the International Myeloma Foundation Nurse Leadership Board. In this informative session, Beth answers questions and provides insights about multiple myeloma, bone marrow transplants, and various aspects…
Videos
During Blood Cancer Awareness Month, Danielle Doheny, Director of Public Policy and Advocacy at the International Myeloma Foundation (IMF), hosted a live Q&A to discusses myeloma advocacy, health policy, and the importance of patient voices. Discover the impact of "oral parity" and learn how…
Audio
On this episode of “Transforming Biopharma,” Managing Partner of ZS Associates Maria Whitman talks with International Myeloma Foundation (IMF) President and CEO Yelak Biru on how he merged his 25 years of data analytic expertise at Fortune 500 companies with his 28 years of living with the…
News Article
International Myeloma Foundation (IMF) to hold first-ever AMN Awards Ceremony at the 7th AMN Summit in Bangkok, Thailand on October 21
BANGKOK, OCTOBER 21, 2023—The International Myeloma Foundation (IMF) announced that it will be holding its first-ever Asian Myeloma…
News Article
The European Medicines Agency's (EMA) Committee for Human Medicines (CHMP) has recommended conditional marketing authorization for ELREXFIOTM (elranatamab) as a standalone treatment for adult patients with relapsed and refractory multiple myeloma. These patients must have undergone at least three…
Videos
As overall survival in myeloma continues to increase, there is an opportunity to improve outcomes further with nutrition and lifestyle interventions and this can no longer be ignored. In this IMF Living Well With Myeloma Webinar, Dr. Shah discusses the scientific evidence behind dietary guidance…
Videos
SpineJack and How It Can Benefit Myeloma Patients
SpineJack involves inserting a small jack into a collapsed vertebra, lifting the collapsed area to create space for the injection of hardening cement. This process aims to raise the vertebra's height and alleviate pain. SpineJack could be…
Videos
The International Myeloma Working Group's Primary Focus is Identifying Unmet Needs within the Myeloma Community and Advancing Myeloma Knowledge
The IMWG has developed crucial criteria for diagnosis (such as the "2/20/20 system" for high-risk smoldering myeloma), the Immune Therapy Registry, the…
News Article
In this interview with Cure Today, IMF Chief Medical Officer Dr. Joseph Mikhael discusses recent advancements in stem cell mobilization in autologous stem cell transplants. These advancements involve using G-CSF and Aphexda in combination to improve stem cell collection efficiency compared to G-CSF…
News Article
AbbVie has announced data from its Phase III CANOVA study, which evaluated the safety and efficacy of venetoclax plus dexamethasone for patients with t(11;14)-positive relapsed or refractory multiple myeloma. The results did not show a significant improvement in progression-free survival…